Supreme Court Turns Away CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court declined to hear CareDx's appeal against Natera in a false-advertising case, leaving a lower court ruling intact.
The U.S. Supreme Court has refused to take up CareDx's appeal in its false-advertising battle with Natera, effectively closing the door on CareDx's bid to overturn an earlier ruling that went against it. When the Supreme Court rejects a petition like this, it doesn't weigh in on the merits — it simply lets the lower court's decision stand. That's a clean win for Natera.
For traders watching NTRA, this is meaningful. Legal overhangs can suppress a stock for months. With the Supreme Court slamming the door shut, Natera removes one more layer of uncertainty from its story. CareDx, on the other hand, has officially exhausted its federal appellate options on this particular dispute.
Read more Jobs Report, Home Prices, Nike Earnings: What to Watch →
The case centered on false-advertising claims — a serious allegation in the competitive molecular diagnostics space where both companies operate. Natera's flagship transplant-monitoring test, Prospera, competes directly against CareDx products. Marketing language in this niche matters because clinicians rely on it when choosing between tests.
This outcome reinforces Natera's legal position heading into what remains a fierce commercial rivalry. CareDx isn't going away as a competitor, but it won't get another shot at reversing this ruling through the courts. Watch how both stocks react — Supreme Court denials tend to be priced in fast.
Continue reading at Yahoo Finance.
